The objective of this event is to connect important actors in the field of immunology, vaccinology, virology, epidemiology, oncology and other disciplines, contributing to research and development of next generation vaccines and immunotherapy.
After some inspiring presentations and pitches, participants can have pre-booked 1-1 meetings during the B2B matchmaking session.
The event focuses on Next Generation Vaccines & Immunotherapy, spotlighting advancements and innovations in vaccine and immunotherapy research and development. During this networking afternoon, speakers can share their expertise on cutting-edge vaccine platform technologies, broad-spectrum vaccine strategies, novel biomarker discovery tools, enhanced vaccine delivery systems, artificial intelligence, and other successful technologies and supporting services that will help to prevent us from existing and emerging pathogens. Furthermore, we can also delve into the groundbreaking research driving the remarkable progress in immunotherapy. This research not only fuels the development of new biomarkers but also paves the way for next-generation cell therapies, cancer vaccines, multi-specific antibodies and other clinically significant breakthroughs.
Meet our speakers:
AGENDA
13:30 Welcome by Flanders Vaccine
13:40 Plenary session
- EATRIS: providing the right tools, at the right time, for vaccine development in a pandemic – David Morrow, EATRIS
- A first-in-human study of a novel adjuvant for increased immunogenicity and dose-sparing of seasonal influenza vaccines – Bart Jacobs, Ghent University Hospital
14:30 Pitch session
- Presenting LVT-001, a unique mucosal vaccine up to stop viral infection contagiousness – Serge Pampfer, Lovaltech
- Therapeutic vaccination with auto-antigen mRNA loaded Tol-cLNP cures murine model of multiple sclerosis – Paulien Baeten, Hasselt University & etherna BV
- XVR013m, a variant-proof antibody with exceptional potency to prevent and treat COVID-19 – Viki Bockstal, ExeVir
- Innovative Antigen Design: Integrating AI and cryoEM for Next-Generation Vaccines – Moises Maestro, PUXANO
- Intratumoral administration of autologous myeloid dendritic cells with the immunologic adjuvant AS01B in refractory advanced melanoma: a phase I clinical trial – Manon Vounckx, VUB
- P95: From Epidemiology Consulting to Comprehensive Vaccine CRO – Kaatje Bollaerts, P95
- High-sensitive immunopeptidomics uncovers actionable antigens paving the way for optimized vaccine development – Pieter-Paul Strybol, ImmuneSpec
- New class of cancer vaccine based on an off-the-shelf Antigen Presenting Cell line (PDC*line) – Eric Halioua, PDC*line Pharma
15:15 Coffee Break
15:30 Start Partnering: 1-1 meetings
17:00 End
TARGET GROUP
The event is open to academia, industry, governmental organisations and everyone who is active in the field of vaccines and immunotherapy.
INTERESTED IN PITCHING?
The call for abstracts is closed.
Do you have expertise within the field of vaccine development, immunotherapy in human or animal health that contributes to the development of next generation vaccines and immunotherapy? Then here’s your opportunity to briefly showcase your expertise to an audience of potential partners.
What’s in it for you?
- You’ll have the opportunity to present your project to an audience of interested partners
- You gain additional visibility for the B2B session of the event
*Submit your abstract before May 16th, 2024
PRACTICAL INFORMATION
- Venue: Park Inn by Radisson Leuven, Martelarenlaan 36, 3010 Leuven
- Access: How to get there?
- Date: 13 June 2024
- Timing: 13:30 -17:00
REGISTRATION
- Flanders Vaccine member: 70 EUR (VAT excl.)
- Flanders Vaccine non-member: 120 EUR (VAT excl.)
SUPPORTING PARTNER
